Cryptococcosis Market Report 2026

The cryptococcosis market size has grown strongly in recent years. It will grow from $7.07 billion in 2025 to $7.71 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to high hiv aids prevalence, increasing organ transplant procedures, limited early diagnostic capabilities, reliance on amphotericin b therapy, hospital-centered infection management.

The cryptococcosis market size is expected to see strong growth in the next few years. It will grow to $10.8 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to improved fungal diagnostics, expanding immunocompromised population, rising awareness of cryptococcal meningitis, development of safer antifungal regimens, improved access to healthcare services. Major trends in the forecast period include rising focus on early fungal infection diagnosis, increased use of combination antifungal therapy, growing monitoring of immunocompromised patients, expansion of hospital-based fungal care, improved access to molecular diagnostic methods.

The increasing incidence of respiratory infections is expected to drive the growth of the cryptococcosis market in the coming years. Respiratory infections affect the respiratory system, including the nose, throat, airways, and lungs, and are caused by pathogens such as viruses, bacteria, or fungi. The rise in respiratory infections is linked to increasing air pollution, as harmful pollutants such as smoke, dust, and chemicals impair lung function and heighten susceptibility to illness. A weakened immune system creates favorable conditions for opportunistic diseases such as cryptococcosis to develop. This fungal infection primarily targets the lungs and central nervous system and poses significant risks to immunocompromised individuals. For example, in December 2024, according to the Australian Bureau of Statistics, an Australia-based government agency, influenza-related deaths increased in 2024, with 951 deaths recorded, compared with 427 deaths in 2022. Therefore, the growing incidence of respiratory infections is contributing to the expansion of the cryptococcosis market.

The rising prevalence of human immunodeficiency virus (HIV) is also expected to propel the growth of the cryptococcosis market going forward. HIV is a virus that attacks the immune system, particularly CD4 cells, leaving the body more susceptible to infections and diseases. The prevalence of HIV is increasing due to limited awareness and education regarding its transmission and prevention, which can lead to risky behaviors, delayed diagnosis, and higher rates of unintentional transmission. As HIV weakens immune defenses, affected individuals become more vulnerable to opportunistic infections such as cryptococcosis. An increase in HIV cases elevates the risk of cryptococcal infections, driving demand for effective treatment options and supporting market growth. For instance, in October 2024, according to the UK Health Security Agency, a UK-based government agency, there were 6,008 HIV diagnoses in 2023, representing a 51 percent increase from 3,975 cases reported in 2022. Therefore, the increasing prevalence of HIV is driving the growth of the cryptococcosis market.

Major companies operating in the cryptococcosis market are actively conducting clinical trials to develop safer and more effective antifungal therapies. Clinical trials play a crucial role in evaluating new treatments and improving outcomes for patients with severe fungal infections. For example, in August 2023, Matinas BioPharma Holdings Inc., a US-based clinical-stage biopharmaceutical company, reported positive results from its Phase II EnACT trial assessing MAT2203 for the treatment of cryptococcal meningitis. MAT2203 is an oral lipid nanocrystal formulation of amphotericin B that targets fungal cell membranes, leading to structural disruption and fungal cell death. The trial demonstrated improved patient survival and a favorable safety profile, underscoring its potential as an important advancement in the treatment of cryptococcosis, including cryptococcal meningitis.

Major companies operating in the cryptococcosis market are Pfizer Inc, Johnson & Johnson, Merck and Co Inc, Abbott Laboratories, Gilead Sciences Inc, Asahi Kasei Pharma Corporation, Viatris Inc, Astellas Pharma Inc, Bausch Health Companies Inc, Sun Pharmaceutical Industries Ltd, Cipla Limited, Dr Reddys Laboratories, Century Pharmaceuticals Ltd, Beijing Lunarsun Pharmaceutical Co Ltd, Matinas Biopharma Holdings Inc, LGM Pharma, Atom Pharma, Brundavan Laboratories Pvt Ltd, Amar Healthcare, Novartis AG, Sanofi SA, Bristol Myers Squibb, Teva Pharmaceutical Industries Ltd, Lupin Limited, Glenmark Pharmaceuticals Ltd.

North America was the largest region in the cryptococcosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cryptococcosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cryptococcosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cryptococcosis market by increasing costs of imported antifungal drugs, diagnostic reagents, and laboratory consumables. Hospitals and research institutes in North America and Europe are most affected due to reliance on imported antifungal therapies, while Asia-Pacific faces higher diagnostic input costs. These tariffs are increasing treatment expenses. However, they are also encouraging domestic antifungal drug production and localized diagnostic manufacturing.

The cryptococcosis market research report is one of a series of new reports that provides cryptococcosis market statistics, including cryptococcosis industry global market size, regional shares, competitors with a cryptococcosis market share, detailed cryptococcosis market segments, market trends and opportunities, and any further data you may need to thrive in the cryptococcosis industry. This cryptococcosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cryptococcosis is a fungal infection caused by Cryptococcus species, including Cryptococcus neoformans and Cryptococcus gattii, that mainly affects the lungs and the central nervous system. It most commonly occurs in individuals with weakened immune systems, such as those living with human immunodeficiency virus or acquired immunodeficiency syndrome, organ transplant recipients, and patients receiving immunosuppressive therapies. The infection can progress to cryptococcal meningitis, which can be life threatening if not treated promptly.

The primary treatment types for cryptococcosis include adjunctive therapies and antifungal medications. Adjunctive therapies are supportive treatments used in combination with primary therapies to improve effectiveness, enhance patient outcomes, or manage treatment-related side effects. Diagnostic techniques used for cryptococcosis include culture-based methods, microscopic examination, and molecular diagnostic approaches, which support the management of conditions such as cerebral cryptococcosis and pulmonary cryptococcosis. These treatments and diagnostic services are utilized across end users including clinics, home healthcare settings, hospitals, and research institutes.

The cryptococcosis market consists of revenues earned by entities by providing services such as diagnostic testing, antifungal treatment, hospital care, disease management, telemedicine consultations, research and development, clinical trials, patient monitoring, and epidemiological surveillance. The market value includes the value of related goods sold by the service provider or included within the service offering. The cryptococcosis market also includes sales of amphotericin B, flucytosine, fluconazole, and voriconazole. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.